发明名称 UREA COMPOUNDS AS INHIBITORS FOR VLA-4
摘要 A compound of formula (I) where D is a VLA-4 specificity determinant which does not impart significant IIB/IIIa activity; R<41> is a group of the formula (V): U - (CH2)d - V - T wherein U is selected from oxygen, sulphur, a direct bond or -CH2O-, V is selected from nitrogen, oxygen, sulphur, S(O), S(O)2 or a direct bond, d is zero or a number from 1 to 4, and T is selected from a range of variables defined in the application; and other variables are defined in the application, or a pharmaceutically acceptable salt or <i>in vivo</i> hydrolysable derivative thereof. The compounds are useful in the treatment of disease mediated by the interaction between VCAM-1 and/or fibronectin and the integrin receptor alpha 4 beta 1. Pharmaceutical compositions and methods of use or treatment are also described and claimed.
申请公布号 WO0153279(A1) 申请公布日期 2001.07.26
申请号 WO2001GB00162 申请日期 2001.01.17
申请人 ASTRAZENECA AB;ASTRAZENECA UK LIMITED;JOHNSTONE, CRAIG;LARGE, MICHAEL, STEWART 发明人 JOHNSTONE, CRAIG;LARGE, MICHAEL, STEWART
分类号 C07D295/08;A61K31/17;A61K31/192;A61K31/40;A61K31/445;A61K31/4453;A61K31/4465;A61K31/5375;A61P11/06;A61P19/02;A61P25/00;A61P29/00;A61P35/04;A61P37/08;A61P43/00;C07C273/00;C07C275/42;C07C317/18;C07C323/12;C07D211/22;C07D211/46;C07D211/54;C07D211/96;C07D295/092;(IPC1-7):C07D295/08;A61K31/537 主分类号 C07D295/08
代理机构 代理人
主权项
地址